RESEARCHER PROFILE (Filmed November 2023)
Dr Felicity Han, Research Fellow
Australian Institute for Bioengineering and Nanotechnology
University of Queensland, Australia
Applying nanotechnology to chronic pain management
Dr Felicity Han is a Research Fellow and Leader in Pain Relief Innovation, at the Australian Institute for Bioengineering and Nanotechnology in the University of Queensland. Dr Han’s research interests sit at the interface of drug delivery and the pain field. Her overarching research goal is to improve the quality of day to day life of patients suffering from chronic pain, by applying nanotechnology to the development of novel highly effective pain-killer products for improving chronic pain management.
Dr Han’s team have developed five different techniques to produce painkiller-loaded nanoparticles and nanofibers aimed at improving pain relief for patients where available pain-killers either lack efficacy or produce dose-limiting side-effects. With the use of their nanoparticles, Dr Han’s team aim to turn a small but potent peptide that has been on the market for over a decade into an oral treatment for improving pain management that currently lacks efficacy in patients. T
Dr Han’s research focuses on developing drug-products to solve one of the largest unmet medical needs in the pain field through the use of sustainable materials. Her team are currently working on developing multifunctional sutures including biodegradable pain relief sutures and innovative novel nanoparticles, which deliver innate-immune targeting peptides for the treatment of cancer and cancer-related pain. Their research also investigates the role of C5a and C3a in the pathogenesis of chronic pain including neuropathic pain, cancer-related pain, low back pain, and OA pain.
Dr Han works in collaboration with other leading Australian and international researchers to stay at the forefront of the drug delivery systems field and the pain field. They also provide a preclinical evaluation of novel compounds and formulations.
Dr Han enjoy’s volunteering within the academic community, most notably as Head of the SBMS ECR Committee and Treasurer for The Queensland Chinese Association of Scientists and Engineers (QCASE). Currently, she is serving as a guest editor of Pain Research and Management.
-
World-first clinical trial improves patient outcomes for kidney transplants (2023)
A world-first clinical trial conducted at the Royal Adelaide Hospital (RAH) and at hospitals across Australia and New Zealand has identified the best fluid treatment to reduce the risk of patients requiring dialysis after a kidney transplant.
Around one in three people who receive a kidney transplant suffer delayed graft function, which means the transplant doesn’t work immediately and they require dialysis.
The lead-author of the study, was Royal Adelaide Hospital Nephrologist and University of Adelaide researcher, Dr Michael Collins.
-
Infections and other lung diseases using models of human lung tissue grown from stem cells
Dr Rhiannon Werder is a Team Leader at Murdoch Children’s Research Institute leading a multidisciplinary team, combining expertise in stem cell biology and immunology, to develop new therapies for lung diseases. Her research centres around induced pluripotent stem cells to investigate respiratory diseases, spanning acute respiratory infections to chronic lung diseases. Using stem cells, Dr Werder’s team creates models of human lung tissue. With these models, Dr Werder is investigating how human-specific pathogens infect different regions of the lung, the ensuing immune responses, and how the lung repairs itself after infections, especially in people with preexisting lung diseases.
-
Benefits of prehabilitation ahead of surgery
Dr Matthew Wallen PhD, AES, AEP is a Senior Research Fellow in Cancer Survivorship, the Deputy Lead of the Cancer Survivorship Program, and a Senior Lecturer in Exercise Science and Clinical Exercise Physiology within the College of Nursing and Health Sciences at Flinders University, in South Australia. His clinical interest focuses on improving outcomes for people requiring major surgery, specifically (1) lifestyle interventions, including exercise, nutritional, and psychological support to improve the health and wellbeing of people prior to surgery, termed ‘prehabilitation’, (2) novel physical function assessments aimed at identifying people at risk of treatment-related complications, and (3) implementation of new models of care in cancer.
